During the past decade, Azienda Ospedaliera Papardo conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 2 clinical trials were completed, i.e. on average, 9.1% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 1 clinical trials were completed. i.e. 10% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Papardo" #1 sponsor was "Fondazione Italiana Linfomi ONLUS" with 16 trials, followed by "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 4 trials sponsored, "Associazione Angela Serra per la ricerca sul cancro" with 2 trials sponsored, "Consorzio Oncotech" with 2 trials sponsored and "Daiichi Sankyo, Inc." with 2 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Papardo" #1 collaborator was "Fondazione Italiana Linfomi ONLUS" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 2 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Papardo" are "Breast Cancer" (5 trials), "Leukemia" (5 trials), "Metastatic Breast Cancer" (3 trials), "Multiple Myeloma" (3 trials) and "Diffuse Large B-Cell Lymphoma" (2 trials). Many other conditions were trialed in "Azienda Ospedaliera Papardo" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Papardo" are "Drug" (35 trials), "Other" (4 trials), "Procedure" (4 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (3 trials), "Atezolizumab" (2 trials), "Everolimus" (2 trials), "Ibrutinib" (2 trials) and "Lapatinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Papardo" are 46 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Papardo". undefined are not yet recruiting, 9 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Azienda Ospedaliera Papardo, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Papardo, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".